<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02930018</url>
  </required_header>
  <id_info>
    <org_study_id>NA-1-007</org_study_id>
    <nct_id>NCT02930018</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Nerinetide (NA-1) in Subjects Undergoing Endovascular Thrombectomy for Stroke</brief_title>
  <acronym>ESCAPE-NA1</acronym>
  <official_title>A Multicentre, Randomized, Double-blinded, Placebo-controlled, Parallel Group, Single-dose Design to Determine the Efficacy and Safety of Intravenous NA-1 in Subjects With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NoNO Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Calgary</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>NoNO Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The ESCAPE-NA-1 study is designed to determine the safety and efficacy of the&#xD;
      neuroprotectant, Nerinetide (NA-1), in reducing global disability in subjects with major&#xD;
      acute ischemic stroke (AIS) with a small established infarct core and with good collateral&#xD;
      circulation who are selected for endovascular revascularization.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Trial Objectives:&#xD;
&#xD;
      The primary objective is to determine the efficacy of the neuroprotectant, Nerinetide, in&#xD;
      reducing global disability in subjects with major acute ischemic stroke (AIS) with a small&#xD;
      established infarct core and with good collateral circulation selected for rapid endovascular&#xD;
      revascularization.&#xD;
&#xD;
      The secondary objectives are to determine the efficacy of Nerinetide in:&#xD;
&#xD;
        -  Reducing functional dependence&#xD;
&#xD;
        -  Improving neurological outcome&#xD;
&#xD;
        -  Improving activities of daily living&#xD;
&#xD;
        -  Reducing mortality rate The leading safety objectives are to determine the effect of&#xD;
           administering a dose of 2.6 mg/kg (up to a maximum dose of 270 mg) intravenous (IV)&#xD;
           infusion of Nerinetide to subject with acute stroke who are selected for endovascular&#xD;
           revascularization on serious adverse events (SAEs) and 90-day mortality.&#xD;
&#xD;
      Trial Design:&#xD;
&#xD;
      This study is a Phase 3, randomized, multicentre, blinded, placebo-controlled, parallel&#xD;
      group, single-dose design. Subjects harboring an acute ischemic stroke and who are selected&#xD;
      for endovascular revascularization in accordance with local institutional practices and who&#xD;
      harbor a small established infarct core and with good collateral circulation will be given a&#xD;
      single, 2.6 mg/kg (up to a maximum dose of 270 mg) intravenous dose of Nerinetide (NA-1) or&#xD;
      placebo as soon as they are deemed to have met the enrollment criteria and with the intention&#xD;
      of starting administration within 30 minutes of randomization. The randomization will be by&#xD;
      stochastic minimization to balance baseline factors.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2017</start_date>
  <completion_date type="Actual">November 20, 2019</completion_date>
  <primary_completion_date type="Actual">November 20, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects With mRS Score of 0 to 2</measure>
    <time_frame>90 Days</time_frame>
    <description>Overall number of subjects experiencing a favorable functional outcome 90 days post-randomization, defined as 0 to 2 on the mRS.&#xD;
The modified Rankin Scale (mRS) is a valid and reliable clinician-reported measure of global disability that has been widely applied for evaluating recovery from stroke. It is a scale used to measure functional recovery (the degree of disability or dependence in daily activities) of people who have suffered a stroke. mRS scores range from 0 (best outcome) to 6 (worst outcome), with 0 indicating no residual symptoms; 5 indicating bedbound, requiring constant care; and 6 indicating death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With NIHSS Score of 0 to 2</measure>
    <time_frame>90 Days or the last rating</time_frame>
    <description>Number of subjects with good neurological outcome, as defined by a score of 0 to 2 on the NIHSS at Day 90 or the last rating.&#xD;
The National Institutes of Health Stroke Scale (NIHSS) is a standardized neurological examination score that is a valid and reliable measure of disability and recovery after acute stroke. Scores range from 0 to 42, with higher scores indicating increasing severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality Rate</measure>
    <time_frame>90 Days</time_frame>
    <description>Mortality rate, as defined by event rate (%) for mortality over the 90-day study period</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1105</enrollment>
  <condition>Stroke, Acute</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Drug vehicle only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nerinetide (NA-1), 2.6 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nerinetide (NA-1), 2.6 mg/kg</intervention_name>
    <description>Single intravenous infusion of nerinetide over 10 Â± 1 minutes</description>
    <arm_group_label>Nerinetide (NA-1), 2.6 mg/kg</arm_group_label>
    <other_name>NA-1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo Comparator: Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Drug vehicle only</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Acute ischemic stroke (AIS) for immediate endovascular treatment&#xD;
&#xD;
          2. Age 18 or greater.&#xD;
&#xD;
          3. Onset (last-seen-well) time to randomization time within 12 hours.&#xD;
&#xD;
          4. Disabling stroke defined as a baseline National Institutes of Health Stroke Score&#xD;
             (NIHSS) &gt; 5 at the time of randomization.&#xD;
&#xD;
          5. Pre-stroke (24 hours prior to stroke onset) independent functional status in&#xD;
             activities of daily living with modified Barthel Index (BI) &gt; 90 (95 or 100). Patient&#xD;
             must be living in their own home, apartment or seniors lodge where no nursing care is&#xD;
             required.&#xD;
&#xD;
          6. Confirmed symptomatic intracranial occlusion, based on multiphase or dynamic&#xD;
             computerized tomographic angiography (CTA), at one or more of the following locations:&#xD;
             Intracranial carotid T/L, M1 middle cerebral artery (MCA). Functionally, when defining&#xD;
             the M1 or the M2, the bulk of the MCA territory must be ischemic.&#xD;
&#xD;
          7. Non-contrast computed tomography (NCCT) and CTA (multiphase or dynamic) for trial&#xD;
             eligibility performed or repeated at ESCAPE-NA1 stroke centre with endovascular suite&#xD;
             on-site.&#xD;
&#xD;
          8. Endovascular treatment with declared first endovascular approach as either stent&#xD;
             retriever or aspiration device, and intended to be initiated (arterial access) within&#xD;
             60 minutes of baseline/qualifying NCCT and to first recanalization of 90 minutes.&#xD;
             Study drug intended to be administered within 60 minutes of the baseline/qualifying&#xD;
             NCCT.&#xD;
&#xD;
          9. Signed informed consent from subject or legally authorized representative or, if&#xD;
             required to enable inclusion by applicable national laws and regulations and the&#xD;
             applicable independent review boards/Ethics Committee requirements for obtaining&#xD;
             consent, from the investigator after consultation with an independent physician who is&#xD;
             not otherwise participating in the trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Evidence of a large core of established infarction defined as ASPECTS 0-4.&#xD;
&#xD;
          2. Evidence of absence of collateral circulation on CTA (Collateral score of 0 or 1).&#xD;
&#xD;
          3. Intent to use any endovascular device other than a stent retriever or clot aspiration&#xD;
             device or intra-arterial medications as the initial thrombectomy approach.&#xD;
&#xD;
          4. Intent to use any intravenous thrombolytic other than alteplase if intravenous&#xD;
             thrombolysis is planned.&#xD;
&#xD;
          5. No femoral pulses, very difficult endovascular access or extreme tortuosity of great&#xD;
             vessels that is predicted to result in an inability to deliver timely endovascular&#xD;
             therapy. Direct common carotid or radial/brachial/axillary access is permissible.&#xD;
&#xD;
          6. Estimated or known weight &gt; 120 kg or &lt; 45 kg.&#xD;
&#xD;
          7. Pregnancy; if a woman is of childbearing potential a urine or serum beta human&#xD;
             chorionic gonadotropin (Î²-hCG) test is positive, or breastfeeding.&#xD;
&#xD;
          8. Severe contrast allergy or absolute contraindication to iodinated contrast preventing&#xD;
             endovascular intervention, including any contraindications listed in the prescribing&#xD;
             information approved by local authorities (e.g., patients with decompensated heart&#xD;
             failure as a contraindication for the use of VISIPAQUEâ¢ 270 in Germany).&#xD;
&#xD;
          9. Clinical history, past imaging or clinical judgment suggests that the intracranial&#xD;
             occlusion is chronic or there is suspected intracranial dissection such that there is&#xD;
             a predicted lack of success with endovascular intervention.&#xD;
&#xD;
         10. Prior enrolment in the ESCAPE-NA1 trial or prior receipt of NA-1 for any reason.&#xD;
&#xD;
         11. Severe known renal impairment defined as requiring dialysis (hemo- or peritoneal) or&#xD;
             if known a creatinine clearance &lt; 29 mL/min.&#xD;
&#xD;
         12. Patient has a severe or fatal comorbid illness that will prevent improvement or&#xD;
             follow-up.&#xD;
&#xD;
         13. Patient cannot complete follow-up treatment due to co-morbid non-fatal illness or they&#xD;
             are known to be a visitor to the city or any other known reason for which follow-up&#xD;
             would be impossible (e.g. incarcerated in a federal prison).&#xD;
&#xD;
         14. Participation in another clinical trial investigating a drug, medical device, or a&#xD;
             medical procedure in the 30 days preceding study inclusion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael D Hill, MD MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Calgary</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ronald Reagan UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Pacific Medical Center - Davies Campus</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Little Company of Mary Medical Center Torrance</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale New Haven Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Health Medical Center</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grady Memorial Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>WellStar Health Systems</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts Medical School</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Luke's Hospital of Kansas City</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Lutheran Medical Center</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novant Health Forsyth Medical Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riverside Radiology</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abington Memorial Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC Presbyterian</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chattanooga Center for Neurologic Research</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valley Baptist Medical Center</name>
      <address>
        <city>Harlingen</city>
        <state>Texas</state>
        <zip>78550</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center- Cherry Hill Campus</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Parkville</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Calgary - Foothills Medical Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N2T9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vancouver Stroke Program Research Office/ Vancouver General Hosptial</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth II Health Science Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 3A7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamilton General Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre- University Hospital</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4E9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Health Network - Toronto Western Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUM Hopital Notre-Dame</name>
      <address>
        <city>MontrÃ©al</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montreal Neurological Institute and Hospital</name>
      <address>
        <city>MontrÃ©al</city>
        <state>Quebec</state>
        <zip>H3A1A1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Quebec- Universite Laval- Hopital de l'Enfant-Jesus</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1J 1Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal University Hospital</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 0W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UniversitÃ¤tsklinikum Carl Gustav Carus Dresdner Neurovaskulares Centrum</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik fÃ¼r Radiologie und Neuroradiologie</name>
      <address>
        <city>Essen</city>
        <zip>D - 45131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Goettingen</name>
      <address>
        <city>GÃ¶ttingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UniversitÃ¤tsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologische Klinik, UniversitÃ¤t Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beaumont Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mater Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dongsan Medical Centre</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inha University Hospital</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yonsei Univ, Severence</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SkÃ¥ne University Hospital</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinksa Institutet</name>
      <address>
        <city>Stockholm</city>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Hospital</name>
      <address>
        <city>Belfast</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Korea, Republic of</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Hill MD, Martin RH, Mikulis D, Wong JH, Silver FL, Terbrugge KG, Milot G, Clark WM, Macdonald RL, Kelly ME, Boulton M, Fleetwood I, McDougall C, Gunnarsson T, Chow M, Lum C, Dodd R, Poublanc J, Krings T, Demchuk AM, Goyal M, Anderson R, Bishop J, Garman D, Tymianski M; ENACT trial investigators. Safety and efficacy of NA-1 in patients with iatrogenic stroke after endovascular aneurysm repair (ENACT): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2012 Nov;11(11):942-50. doi: 10.1016/S1474-4422(12)70225-9. Epub 2012 Oct 8.</citation>
    <PMID>23051991</PMID>
  </reference>
  <reference>
    <citation>Cook DJ, Teves L, Tymianski M. Treatment of stroke with a PSD-95 inhibitor in the gyrencephalic primate brain. Nature. 2012 Feb 29;483(7388):213-7. doi: 10.1038/nature10841.</citation>
    <PMID>22388811</PMID>
  </reference>
  <reference>
    <citation>Cook DJ, Teves L, Tymianski M. A translational paradigm for the preclinical evaluation of the stroke neuroprotectant Tat-NR2B9c in gyrencephalic nonhuman primates. Sci Transl Med. 2012 Oct 3;4(154):154ra133. doi: 10.1126/scitranslmed.3003824.</citation>
    <PMID>23035045</PMID>
  </reference>
  <reference>
    <citation>Sun HS, Doucette TA, Liu Y, Fang Y, Teves L, Aarts M, Ryan CL, Bernard PB, Lau A, Forder JP, Salter MW, Wang YT, Tasker RA, Tymianski M. Effectiveness of PSD95 inhibitors in permanent and transient focal ischemia in the rat. Stroke. 2008 Sep;39(9):2544-53. doi: 10.1161/STROKEAHA.107.506048. Epub 2008 Jul 10.</citation>
    <PMID>18617669</PMID>
  </reference>
  <reference>
    <citation>Aarts M, Liu Y, Liu L, Besshoh S, Arundine M, Gurd JW, Wang YT, Salter MW, Tymianski M. Treatment of ischemic brain damage by perturbing NMDA receptor- PSD-95 protein interactions. Science. 2002 Oct 25;298(5594):846-50.</citation>
    <PMID>12399596</PMID>
  </reference>
  <reference>
    <citation>Sattler R, Xiong Z, Lu WY, Hafner M, MacDonald JF, Tymianski M. Specific coupling of NMDA receptor activation to nitric oxide neurotoxicity by PSD-95 protein. Science. 1999 Jun 11;284(5421):1845-8.</citation>
    <PMID>10364559</PMID>
  </reference>
  <reference>
    <citation>Goyal M, Demchuk AM, Menon BK, Eesa M, Rempel JL, Thornton J, Roy D, Jovin TG, Willinsky RA, Sapkota BL, Dowlatshahi D, Frei DF, Kamal NR, Montanera WJ, Poppe AY, Ryckborst KJ, Silver FL, Shuaib A, Tampieri D, Williams D, Bang OY, Baxter BW, Burns PA, Choe H, Heo JH, Holmstedt CA, Jankowitz B, Kelly M, Linares G, Mandzia JL, Shankar J, Sohn SI, Swartz RH, Barber PA, Coutts SB, Smith EE, Morrish WF, Weill A, Subramaniam S, Mitha AP, Wong JH, Lowerison MW, Sajobi TT, Hill MD; ESCAPE Trial Investigators. Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med. 2015 Mar 12;372(11):1019-30. doi: 10.1056/NEJMoa1414905. Epub 2015 Feb 11.</citation>
    <PMID>25671798</PMID>
  </reference>
  <results_reference>
    <citation>Hill MD, Goyal M, Menon BK, Nogueira RG, McTaggart RA, Demchuk AM, Poppe AY, Buck BH, Field TS, Dowlatshahi D, van Adel BA, Swartz RH, Shah RA, Sauvageau E, Zerna C, Ospel JM, Joshi M, Almekhlafi MA, Ryckborst KJ, Lowerison MW, Heard K, Garman D, Haussen D, Cutting SM, Coutts SB, Roy D, Rempel JL, Rohr AC, Iancu D, Sahlas DJ, Yu AYX, Devlin TG, Hanel RA, Puetz V, Silver FL, Campbell BCV, Chapot R, Teitelbaum J, Mandzia JL, Kleinig TJ, Turkel-Parrella D, Heck D, Kelly ME, Bharatha A, Bang OY, Jadhav A, Gupta R, Frei DF, Tarpley JW, McDougall CG, Holmin S, Rha JH, Puri AS, Camden MC, Thomalla G, Choe H, Phillips SJ, Schindler JL, Thornton J, Nagel S, Heo JH, Sohn SI, Psychogios MN, Budzik RF, Starkman S, Martin CO, Burns PA, Murphy S, Lopez GA, English J, Tymianski M; ESCAPE-NA1 Investigators. Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial. Lancet. 2020 Mar 14;395(10227):878-887. doi: 10.1016/S0140-6736(20)30258-0. Epub 2020 Feb 20.</citation>
    <PMID>32087818</PMID>
  </results_reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 6, 2016</study_first_submitted>
  <study_first_submitted_qc>October 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 11, 2016</study_first_posted>
  <results_first_submitted>October 22, 2020</results_first_submitted>
  <results_first_submitted_qc>November 18, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 14, 2020</results_first_posted>
  <last_update_submitted>November 18, 2020</last_update_submitted>
  <last_update_submitted_qc>November 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Ischemic Stroke</keyword>
  <keyword>Endovascular Thrombectomy</keyword>
  <keyword>Neuroprotection</keyword>
  <keyword>Tat-NR2B9c</keyword>
  <keyword>NA-1</keyword>
  <keyword>Nerinetide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 19, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/18/NCT02930018/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 9, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/18/NCT02930018/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients with acute ischaemic stroke who were selected to undergo EVT (endovascular thrombectomy) were enrolled. The trial was done at acute care hospitals. Patients were randomly assigned (1:1) to receive a single intravenous dose of nerinetide (NA-1) or placebo. All patients underwent endovascular thrombectomy and received alteplase in usual care when indicated.</recruitment_details>
      <pre_assignment_details>The trial drug was administered as soon as possible after randomisation.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Drug vehicle only&#xD;
Placebo: Placebo Comparator: Placebo</description>
        </group>
        <group group_id="P2">
          <title>Nerinetide (NA-1), 2.6 mg/kg</title>
          <description>Single intravenous infusion of nerinetide over 10 Â± 1 minutes</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="556"/>
                <participants group_id="P2" count="549"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="550"/>
                <participants group_id="P2" count="546"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Drug vehicle only&#xD;
Placebo: Placebo Comparator: Placebo</description>
        </group>
        <group group_id="B2">
          <title>Nerinetide (NA-1), 2.6 mg/kg</title>
          <description>Single intravenous infusion of nerinetide over 10 Â± 1 minutes</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="556"/>
            <count group_id="B2" value="549"/>
            <count group_id="B3" value="1105"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.0" lower_limit="20" upper_limit="103"/>
                    <measurement group_id="B2" value="71.0" lower_limit="18" upper_limit="98"/>
                    <measurement group_id="B3" value="70.0" lower_limit="18" upper_limit="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="281"/>
                    <measurement group_id="B2" value="268"/>
                    <measurement group_id="B3" value="549"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="275"/>
                    <measurement group_id="B2" value="281"/>
                    <measurement group_id="B3" value="556"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="540"/>
                    <measurement group_id="B2" value="541"/>
                    <measurement group_id="B3" value="1081"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <description>Under 'Unknown or Not reported' category the number of participants for the 'Other' category is indicated</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="107"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="76"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="453"/>
                    <measurement group_id="B2" value="436"/>
                    <measurement group_id="B3" value="889"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="252"/>
                    <measurement group_id="B2" value="253"/>
                    <measurement group_id="B3" value="505"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Korea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="203"/>
                    <measurement group_id="B2" value="211"/>
                    <measurement group_id="B3" value="414"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ireland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Alteplase Treatment</title>
          <description>Treatment with alteplase as part of standard-of-care in addition to study drug</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Participants treated with alteplase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="329"/>
                    <measurement group_id="B2" value="330"/>
                    <measurement group_id="B3" value="659"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants not treated with alteplase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="227"/>
                    <measurement group_id="B2" value="219"/>
                    <measurement group_id="B3" value="446"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With mRS Score of 0 to 2</title>
        <description>Overall number of subjects experiencing a favorable functional outcome 90 days post-randomization, defined as 0 to 2 on the mRS.&#xD;
The modified Rankin Scale (mRS) is a valid and reliable clinician-reported measure of global disability that has been widely applied for evaluating recovery from stroke. It is a scale used to measure functional recovery (the degree of disability or dependence in daily activities) of people who have suffered a stroke. mRS scores range from 0 (best outcome) to 6 (worst outcome), with 0 indicating no residual symptoms; 5 indicating bedbound, requiring constant care; and 6 indicating death.</description>
        <time_frame>90 Days</time_frame>
        <population>Intent-to-Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Drug vehicle only&#xD;
Placebo: Placebo Comparator: Placebo</description>
          </group>
          <group group_id="O2">
            <title>Nerinetide, 2.6 mg/kg</title>
            <description>Single intravenous infusion of nerinetide over 10 Â± 1 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With mRS Score of 0 to 2</title>
          <description>Overall number of subjects experiencing a favorable functional outcome 90 days post-randomization, defined as 0 to 2 on the mRS.&#xD;
The modified Rankin Scale (mRS) is a valid and reliable clinician-reported measure of global disability that has been widely applied for evaluating recovery from stroke. It is a scale used to measure functional recovery (the degree of disability or dependence in daily activities) of people who have suffered a stroke. mRS scores range from 0 (best outcome) to 6 (worst outcome), with 0 indicating no residual symptoms; 5 indicating bedbound, requiring constant care; and 6 indicating death.</description>
          <population>Intent-to-Treat Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="556"/>
                <count group_id="O2" value="549"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="329"/>
                    <measurement group_id="O2" value="337"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary hypothesis was that administration of nerinetide (NA-1) would result in an increase in the proportion of responders. The primary analysis was a Wald test for treatment group difference in the primary outcome from a logistic regression adjusted for the 2 stratification variables (alteplase use, first declared thrombectomy device), and the 6 covariates used in the minimization. The trial was designed to have 80% power to detect an 8.7% absolute difference between groups.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>It is hypothesized that the cleavage of nerinetide by plasmin which is activated by tissue plasminogen activators, such as alteplase results in a treatment modification of nerinetide in AIS (Acute Ischemic Stroke) patients with prior administration of alteplase as part of standard-of-care.</non_inferiority_desc>
            <p_value>0.335</p_value>
            <p_value_desc>2 sided 0.05 significance level.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.146</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.869</ci_lower_limit>
            <ci_upper_limit>1.511</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With NIHSS Score of 0 to 2</title>
        <description>Number of subjects with good neurological outcome, as defined by a score of 0 to 2 on the NIHSS at Day 90 or the last rating.&#xD;
The National Institutes of Health Stroke Scale (NIHSS) is a standardized neurological examination score that is a valid and reliable measure of disability and recovery after acute stroke. Scores range from 0 to 42, with higher scores indicating increasing severity.</description>
        <time_frame>90 Days or the last rating</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Drug vehicle only&#xD;
Placebo: Placebo Comparator: Placebo</description>
          </group>
          <group group_id="O2">
            <title>Nerinetide, 2.6 mg/kg</title>
            <description>Single intravenous infusion of nerinetide over 10 Â± 1 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With NIHSS Score of 0 to 2</title>
          <description>Number of subjects with good neurological outcome, as defined by a score of 0 to 2 on the NIHSS at Day 90 or the last rating.&#xD;
The National Institutes of Health Stroke Scale (NIHSS) is a standardized neurological examination score that is a valid and reliable measure of disability and recovery after acute stroke. Scores range from 0 to 42, with higher scores indicating increasing severity.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="556"/>
                <count group_id="O2" value="549"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="320"/>
                    <measurement group_id="O2" value="320"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>It is hypothesized that the cleavage of nerinetide by plasmin which is activated by tissue plasminogen activators, such as alteplase results in a treatment modification of nerinetide in AIS patients with prior administration of alteplase as part of standard-of-care.</non_inferiority_desc>
            <p_value>0.866</p_value>
            <p_value_desc>2 sided 0.05 significance level.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.024</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.781</ci_lower_limit>
            <ci_upper_limit>1.342</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mortality Rate</title>
        <description>Mortality rate, as defined by event rate (%) for mortality over the 90-day study period</description>
        <time_frame>90 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Drug vehicle only&#xD;
Placebo: Placebo Comparator: Placebo</description>
          </group>
          <group group_id="O2">
            <title>Nerinetide, 2.6 mg/kg</title>
            <description>Single intravenous infusion of nerinetide over 10 Â± 1 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Mortality Rate</title>
          <description>Mortality rate, as defined by event rate (%) for mortality over the 90-day study period</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="556"/>
                <count group_id="O2" value="549"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>It is hypothesized that the cleavage of nerinetide by plasmin which is activated by tissue plasminogen activators, such as alteplase results in a treatment modification of nerinetide in AIS patients with prior administration of alteplase as part of standard-of-care.</non_inferiority_desc>
            <p_value>0.199</p_value>
            <p_value_desc>2 sided 0.05 significance level.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.776</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.527</ci_lower_limit>
            <ci_upper_limit>1.143</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Number of Subjects With mRS Score of 0 to 2 in the No-alteplase Sub-group</title>
        <description>Overall number of subjects experiencing a favorable functional outcome 90 days post-randomization, defined as 0 to 2 on the mRS in the sub-group of participants not treated with alteplase as part of standard-of-care.&#xD;
The modified Rankin Scale (mRS) is a valid and reliable clinician-reported measure of global disability that has been widely applied for evaluating recovery from stroke. It is a scale used to measure functional recovery (the degree of disability or dependence in daily activities) of people who have suffered a stroke. mRS scores range from 0 (best outcome) to 6 (worst outcome), with 0 indicating no residual symptoms; 5 indicating bedbound, requiring constant care; and 6 indicating death.</description>
        <time_frame>90 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Drug vehicle only&#xD;
Placebo: Placebo Comparator: Placebo</description>
          </group>
          <group group_id="O2">
            <title>Nerinetide, 2.6 mg/kg</title>
            <description>Single intravenous infusion of nerinetide over 10 Â± 1 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With mRS Score of 0 to 2 in the No-alteplase Sub-group</title>
          <description>Overall number of subjects experiencing a favorable functional outcome 90 days post-randomization, defined as 0 to 2 on the mRS in the sub-group of participants not treated with alteplase as part of standard-of-care.&#xD;
The modified Rankin Scale (mRS) is a valid and reliable clinician-reported measure of global disability that has been widely applied for evaluating recovery from stroke. It is a scale used to measure functional recovery (the degree of disability or dependence in daily activities) of people who have suffered a stroke. mRS scores range from 0 (best outcome) to 6 (worst outcome), with 0 indicating no residual symptoms; 5 indicating bedbound, requiring constant care; and 6 indicating death.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113"/>
                    <measurement group_id="O2" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.028</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.657</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.055</ci_lower_limit>
            <ci_upper_limit>2.603</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Absolute Risk Difference (%)</param_type>
            <param_value>9.6</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>The unadjusted absolute risk difference in % between nerinetide and placebo in the no-alteplase subgroup.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Relative Risk Difference (%)</param_type>
            <param_value>19.3</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>The unadjusted relative risk difference in % between nerinetide and placebo in the no-alteplase subgroup.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Number of Subjects With NIHSS Score of 0 to 2 in the No-Alteplase Sub-group</title>
        <description>Number of subjects with good neurological outcome, as defined by a score of 0 to 2 on the NIHSS at Day 90 or the last rating in the sub-group of participants not treated with alteplase as part of standard-of-care.&#xD;
The National Institutes of Health Stroke Scale (NIHSS) is a standardized neurological examination score that is a valid and reliable measure of disability and recovery after acute stroke. Scores range from 0 to 42, with higher scores indicating increasing severity.</description>
        <time_frame>90 days or last rating</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Drug vehicle only&#xD;
Placebo: Placebo Comparator: Placebo</description>
          </group>
          <group group_id="O2">
            <title>Nerinetide, 2.6 mg/kg</title>
            <description>Single intravenous infusion of nerinetide over 10 Â± 1 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With NIHSS Score of 0 to 2 in the No-Alteplase Sub-group</title>
          <description>Number of subjects with good neurological outcome, as defined by a score of 0 to 2 on the NIHSS at Day 90 or the last rating in the sub-group of participants not treated with alteplase as part of standard-of-care.&#xD;
The National Institutes of Health Stroke Scale (NIHSS) is a standardized neurological examination score that is a valid and reliable measure of disability and recovery after acute stroke. Scores range from 0 to 42, with higher scores indicating increasing severity.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113"/>
                    <measurement group_id="O2" value="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.088</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.482</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.943</ci_lower_limit>
            <ci_upper_limit>2.329</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Absolute Risk Difference (%)</param_type>
            <param_value>9.1</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>The unadjusted absolute risk difference in % between nerinetide and placebo in the no-alteplase subgroup.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Relative Risk Difference (%)</param_type>
            <param_value>18.3</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>The unadjusted relative risk difference in % between nerinetide and placebo in the no-alteplase subgroup.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Mortality Rate in the No-Alteplase Sub-group</title>
        <description>Mortality rate, as defined by event rate (%) for mortality over the 90-day study period in the sub-group of participants not treated with alteplase as part of standard-of-care</description>
        <time_frame>90 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Drug vehicle only&#xD;
Placebo: Placebo Comparator: Placebo</description>
          </group>
          <group group_id="O2">
            <title>Nerinetide, 2.6 mg/kg</title>
            <description>Single intravenous infusion of nerinetide over 10 Â± 1 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Mortality Rate in the No-Alteplase Sub-group</title>
          <description>Mortality rate, as defined by event rate (%) for mortality over the 90-day study period in the sub-group of participants not treated with alteplase as part of standard-of-care</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.055</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.572</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.323</ci_lower_limit>
            <ci_upper_limit>1.013</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Absolute Risk Difference (%)</param_type>
            <param_value>7.5</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>The unadjusted absolute risk difference in % between nerinetide and placebo in the no-alteplase subgroup.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Relative Risk Difference (%)</param_type>
            <param_value>39.7</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>The unadjusted relative risk difference in % between nerinetide and placebo in the no-alteplase subgroup.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Number of Subjects With mRS Score of 0 to 2 in the Alteplase Sub-group</title>
        <description>Overall proportion of subjects experiencing a favorable functional outcome 90 days post-randomization, defined as 0 to 2 on the mRS in the sub-group of participants treated with alteplase as part of standard-of-care.&#xD;
The modified Rankin Scale (mRS) is a valid and reliable clinician-reported measure of global disability that has been widely applied for evaluating recovery from stroke. It is a scale used to measure functional recovery (the degree of disability or dependence in daily activities) of people who have suffered a stroke. mRS scores range from 0 (best outcome) to 6 (worst outcome), with 0 indicating no residual symptoms; 5 indicating bedbound, requiring constant care; and 6 indicating death.</description>
        <time_frame>90 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Drug vehicle only&#xD;
Placebo: Placebo Comparator: Placebo</description>
          </group>
          <group group_id="O2">
            <title>Nerinetide, 2.6 mg/kg</title>
            <description>Single intravenous infusion of nerinetide over 10 Â± 1 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With mRS Score of 0 to 2 in the Alteplase Sub-group</title>
          <description>Overall proportion of subjects experiencing a favorable functional outcome 90 days post-randomization, defined as 0 to 2 on the mRS in the sub-group of participants treated with alteplase as part of standard-of-care.&#xD;
The modified Rankin Scale (mRS) is a valid and reliable clinician-reported measure of global disability that has been widely applied for evaluating recovery from stroke. It is a scale used to measure functional recovery (the degree of disability or dependence in daily activities) of people who have suffered a stroke. mRS scores range from 0 (best outcome) to 6 (worst outcome), with 0 indicating no residual symptoms; 5 indicating bedbound, requiring constant care; and 6 indicating death.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="329"/>
                <count group_id="O2" value="330"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="216"/>
                    <measurement group_id="O2" value="207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>It is hypothesized that the cleavage of nerinetide by plasmin which is activated by tissue plasminogen activators, such as alteplase results in a treatment modification of nerinetide in AIS patients with prior administration of alteplase as part of standard-of-care.</non_inferiority_desc>
            <p_value>0.529</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.887</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.612</ci_lower_limit>
            <ci_upper_limit>1.286</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Number of Subjects With NIHSS Score of 0 to 2 in the Alteplase Sub-group</title>
        <description>Number of subjects with good neurological outcome, as defined by a score of 0 to 2 on the NIHSS at Day 90 or the last rating in the sub-group of participants treated with alteplase as part of standard-of-care.&#xD;
The National Institutes of Health Stroke Scale (NIHSS) is a standardized neurological examination score that is a valid and reliable measure of disability and recovery after acute stroke. Scores range from 0 to 42, with higher scores indicating increasing severity.</description>
        <time_frame>90 days or last rating</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Drug vehicle only&#xD;
Placebo: Placebo Comparator: Placebo</description>
          </group>
          <group group_id="O2">
            <title>Nerinetide, 2.6 mg/kg</title>
            <description>Single intravenous infusion of nerinetide over 10 Â± 1 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With NIHSS Score of 0 to 2 in the Alteplase Sub-group</title>
          <description>Number of subjects with good neurological outcome, as defined by a score of 0 to 2 on the NIHSS at Day 90 or the last rating in the sub-group of participants treated with alteplase as part of standard-of-care.&#xD;
The National Institutes of Health Stroke Scale (NIHSS) is a standardized neurological examination score that is a valid and reliable measure of disability and recovery after acute stroke. Scores range from 0 to 42, with higher scores indicating increasing severity.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="329"/>
                <count group_id="O2" value="330"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="207"/>
                    <measurement group_id="O2" value="191"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>It is hypothesized that the cleavage of nerinetide by plasmin which is activated by tissue plasminogen activators, such as alteplase results in a treatment modification of nerinetide in AIS patients with prior administration of alteplase as part of standard-of-care.</non_inferiority_desc>
            <p_value>0.181</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.782</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.545</ci_lower_limit>
            <ci_upper_limit>1.121</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Mortality Rate in the Alteplase Sub-group</title>
        <description>Mortality rate, as defined by event rate (%) for mortality over the 90-day study period in the sub-group of participants treated with alteplase as part of standard-of-care</description>
        <time_frame>90 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Drug vehicle only&#xD;
Placebo: Placebo Comparator: Placebo</description>
          </group>
          <group group_id="O2">
            <title>Nerinetide, 2.6 mg/kg</title>
            <description>Single intravenous infusion of nerinetide over 10 Â± 1 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Mortality Rate in the Alteplase Sub-group</title>
          <description>Mortality rate, as defined by event rate (%) for mortality over the 90-day study period in the sub-group of participants treated with alteplase as part of standard-of-care</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="329"/>
                <count group_id="O2" value="330"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>It is hypothesized that the cleavage of nerinetide by plasmin which is activated by tissue plasminogen activators, such as alteplase results in a treatment modification of nerinetide in AIS patients with prior administration of alteplase as part of standard-of-care.</non_inferiority_desc>
            <p_value>0.869</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.050</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.588</ci_lower_limit>
            <ci_upper_limit>1.874</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events occurring within 30 days of randomization and all Serious Adverse Events up to the end of study visit (Day 90 visit or death) or until the subject was deemed &quot;lost to follow-up&quot; were reported.</time_frame>
      <desc>All Adverse Events (Serious and Non-Serious) were monitored for the Safety Population, which included all subjects who received any amount of study drug (total of 1101 subjects).&#xD;
Adverse Events of Special Interest (AESI) were also collected, and included any Adverse Event which occurred within 2 hours of end of drug infusion and which fall under the standardized MedDRA queries of &quot;Angioedema&quot;, &quot;Anaphylactic reaction&quot;, &quot;Anaphylactic shock&quot; and terms relating to &quot;hypotension&quot;.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Drug vehicle only&#xD;
Placebo: Placebo Comparator: Placebo</description>
        </group>
        <group group_id="E2">
          <title>Nerinetide, 2.6 mg/kg</title>
          <description>Single intravenous infusion of nerinetide over 10 Â± 1 minutes</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="74" subjects_at_risk="556"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="549"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="198" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="181" subjects_at_risk="547"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Cardiac ventricular thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Intracardiac thrombus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Mitral valve stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Sinus arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Stress cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial septal defect</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperparathyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Intestinal ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Mouth haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Peritoneal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Complication associated with device</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Drug withdrawal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Vascular stent occlusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Vessel puncture site haematoma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Vessel puncture site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Vessel puncture site occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Drug-induced liver injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Portal vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Cardiac valve abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Cardiac valve vegetation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Empyema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Stoma site abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="547"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Abdominal wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Cerebral hyperperfusion syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Coronary artery restenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Endotracheal intubation complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Gastrostomy tube site complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Reocclusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Subdural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Traumatic intracranial haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Vascular access site pseudoaneurysm</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Vascular procedure complication</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="547"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hepatic enzyme abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Troponin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bronchial carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Cervix cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Metastasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Myeloid leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Plasma cell myeloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Prostate cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Small intestine adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Brain oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Carotid arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Haemorrhagic transformation stroke</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Lacunar stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Neurological decompensation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Status epilepticus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Stroke in evolution</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Vascular dementia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcohol withdrawal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Post stroke depression</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Azotaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Prostatomegaly</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Choking</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Obstructive airways disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="547"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Loss of personal independence in daily activities</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Left atrial appendage occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Brachiocephalic vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Peripheral artery aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Peripheral artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Peripheral artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="547"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="472" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="474" subjects_at_risk="547"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="547"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="547"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="547"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Vessel puncture site hematoma</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="547"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="547"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Vascular procedure complication</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="547"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="547"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="88" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="79" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Hemorrhagic Transformation Stroke</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="547"/>
              </event>
              <event>
                <sub_title>Stroke In Evolution</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="547"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="547"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="547"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michael Tymianski, MD PhD</name_or_title>
      <organization>NoNO Inc.</organization>
      <phone>4165831687</phone>
      <email>mtymianski@nonoinc.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

